◀ Back to TP53

CREBBP — TP53

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: RELA → Complex of CREBBP-TP53 (decreases, CREBBP/TP53 Activity) Wadgaonkar et al., J Biol Chem 1999*
  Evidence: Nuclear competition for limiting amounts of CBP provides a novel mechanism for altering the balance between the expression of NF-kappaB-dependent proliferation or survival genes and p53-dependent genes
• BioCarta regulation of transcriptional activity by pml: PML/sp100/SUMO1/p53 complex (PML-SP100-TP53-SUMO1) → histone transacetylase (CREBBP) (modification, collaborate)
  
• BioCarta regulation of transcriptional activity by pml: histone transacetylase (CREBBP) → PML/sp100/SUMO1/p53(+1) complex (PML-SP100-TP53-SUMO1) (modification, activates)
  
• FastForward regulation: TP53 → CREBBP (transcriptional regulation, unknown) Wei et al., Cell 2006
  Evidence: DNABINDING
• KEGG Cell cycle: CREBBP/EP300 → TP53 (protein-protein, activation)
• KEGG Prostate cancer: CREBBP/EP300 → TP53 (protein-protein, missing interaction)
• NCI Pathway Database Direct p53 effectors: GCN5-L/ADA2B/TAF9 complex (KAT2A-TADA2B-TAF9) → p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) (transcription, activates)
  An et al., Cell 2004, Gamper et al., Mol Cell Biol 2008
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: nucleus (EP300/CREBBP) → p53 (tetramer) complex (TP53) (transcription, activates)
  Fei et al., Cancer Cell 2004*
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: nucleus (EP300/CREBBP) → p53 (tetramer) complex (TP53) (transcription, activates)
  Saifudeen et al., J Biol Chem 2000*
  Evidence: mutant phenotype, reporter gene, physical interaction, other species
• NCI Pathway Database p53 pathway: p53 (TP53) → MDM2/UBCH5/Cbp/p300 complex (MDM2-UBE2D1-EP300_CREBBP) (proteasomal ubiquitin-dependent protein catabolic process, collaborate)
  Rodriguez et al., Mol Cell Biol 2000, Mayo et al., Proc Natl Acad Sci U S A 2001, Zhou et al., Nat Cell Biol 2001, Li et al., Science 2003, Ferreon et al., Proc Natl Acad Sci U S A 2009, Siepe et al., Nat Cell Biol 2009, Haupt et al., Nature 1997
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database p53 pathway: p53/PIN1 complex (TP53-PIN1) → MDM2/UBCH5/Cbp/p300 complex (MDM2-UBE2D1-EP300_CREBBP) (proteasomal ubiquitin-dependent protein catabolic process, inhibits)
  Rodriguez et al., Mol Cell Biol 2000, Mayo et al., Proc Natl Acad Sci U S A 2001, Zhou et al., Nat Cell Biol 2001, Li et al., Science 2003, Ferreon et al., Proc Natl Acad Sci U S A 2009, Siepe et al., Nat Cell Biol 2009, Haupt et al., Nature 1997
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database p53 pathway: Cbp/p300/SKP2 complex (EP300_CREBBP-SKP2) → p53 (tetramer) complex (TP53) (modification, inhibits)
  Tang et al., Cell 2008
  Evidence: mutant phenotype, assay
• NCI Pathway Database p53 pathway: nucleus (EP300/CREBBP) → p53 (tetramer) complex (TP53) (modification, activates)
  Tang et al., Cell 2008
  Evidence: mutant phenotype, assay
• NCI Pathway Database Direct p53 effectors: p53 (tetramer) complex (TP53) → Cbp/p300/JMY complex (EP300_CREBBP-JMY) (transcription, activates)
  Shikama et al., Mol Cell 1999, Thornborrow et al., J Biol Chem 2001, Thornborrow et al., Oncogene 2002, Hudson et al., J Biol Chem 2005, Sykes et al., Mol Cell 2006
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: PRMT1 (PRMT1) → p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) (modification, collaborate)
  An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) → nucleus (EP300/CREBBP) (modification, collaborate) An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) → CARM1 (CARM1) (modification, collaborate) An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) → p53 (tetramer) complex (TP53) (modification, collaborate)
  An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: nucleus (EP300/CREBBP) → p53 (tetramer) complex (TP53) (modification, collaborate)
  An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Bind Interaction: CREBBP — TP53 Steffan et al., Proc Natl Acad Sci U S A 2000*
• IRef Bind Interaction: CREBBP — TP53 Zeng et al., Mol Cell Biol 2000
• IRef Bind_translation Interaction: CREBBP — TP53 (affinity chromatography technology) Steffan et al., Proc Natl Acad Sci U S A 2000*
• IRef Bind_translation Interaction: CREBBP — TP53 (unspecified method) Zeng et al., Mol Cell Biol 2000
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, pull down) Ferreon et al., Proc Natl Acad Sci U S A 2009
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, enzymatic study) Shi et al., Proc Natl Acad Sci U S A 2009*
• IRef Biogrid Interaction: CREBBP — TP53 (colocalization, imaging technique) Saifudeen et al., American journal of physiology. Renal physiology 2005*
• IRef Biogrid Interaction: CREBBP — TP53 (physical association, affinity chromatography technology) Zhao et al., Mol Cell Biol 2006*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, pull down) Gu et al., Nature 1997*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, pull down) Scolnick et al., Cancer Res 1997*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, pull down) Matsuda et al., J Biol Chem 2004*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, enzymatic study) Pasqualucci et al., Nature 2011*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, unspecified method) Lee et al., Proc Natl Acad Sci U S A 2010*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, pull down) Lee et al., Mol Endocrinol 1999*
• IRef Biogrid Interaction: CREBBP — TP53 (physical association, affinity chromatography technology) Dai et al., Proc Natl Acad Sci U S A 2011*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, enzymatic study) Ito et al., EMBO J 2002*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, pull down) Giebler et al., Mol Cell Biol 2000*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, pull down) Livengood et al., J Biol Chem 2002*
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, enzymatic study) Tang et al., Cell 2008
• IRef Biogrid Interaction: CREBBP — TP53 (direct interaction, fluorescent resonance energy transfer) Jenkins et al., Biochemistry 2009*
• IRef Dip Interaction: CREBBP — TP53 (physical association, anti tag coimmunoprecipitation) Pan et al., Proc Natl Acad Sci U S A 2009*
• IRef Hprd Interaction: TP53 — CREBBP (in vivo) Giebler et al., Mol Cell Biol 2000*, Livengood et al., J Biol Chem 2002*, Gu et al., Nature 1997*
• IRef Hprd Interaction: TP53 — CREBBP (in vitro) Giebler et al., Mol Cell Biol 2000*, Livengood et al., J Biol Chem 2002*, Gu et al., Nature 1997*
• IRef Intact Interaction: Complex of EP300-TP53-CREBBP (association, pull down) Gu et al., Nature 1997*
• IRef Intact Interaction: CREBBP — TP53 (physical association, pull down) Steffan et al., Proc Natl Acad Sci U S A 2000*
• IRef Intact Interaction: CREBBP — TP53 (physical association, competition binding) O'Connor et al., J Virol 1999*
• IRef Intact Interaction: CREBBP — TP53 (physical association, pull down) O'Connor et al., J Virol 1999*
• IRef Intact Interaction: CREBBP — TP53 (physical association, anti bait coimmunoprecipitation) Gu et al., Nature 1997*
• IRef Intact Interaction: CREBBP — TP53 (physical association, pull down) Gu et al., Nature 1997*
• IRef Mppi Interaction: CREBBP — TP53 (copurification) Zeng et al., Mol Cell Biol 2000
• IRef Ophid Interaction: CREBBP — TP53 (aggregation, interologs mapping) Brown et al., Bioinformatics 2005
• STRING interaction: TP53 — CREBBP (interaction, mapped from kegg_pathways)
• STRING interaction: TP53 — CREBBP (interaction, mapped from kegg_pathways)
• STRING interaction: CREBBP — TP53 (interaction, mapped from kegg_pathways)
• STRING interaction: CREBBP — TP53 (interaction, mapped from kegg_pathways)

Text-mined interactions from Literome

Wadgaonkar et al., J Biol Chem 1999 : p53 requires the coactivator CREB binding protein (CBP) , or its structural homolog, p300, to stimulate transcription of responsive genes
Suzuki et al., Int J Cancer 2000 (Mouth Neoplasms...) : TSA enhanced the protein expression of p21 ( WAF1 ), CREB binding protein , cyclinE, cyclin A, Bak and Bax, while it reduced the expression of E2F-1, E2F-4, HDAC1, p53 and hyperphosphorylated form of Rb
Grossman et al., Eur J Biochem 2001 : p300/CBP/p53 interaction and regulation of the p53 response ... Through physical interaction with p53, p300/CBP can both positively and negatively regulate p53 transactivation, as well as p53 protein turnover depending on cellular context and environmental stimuli, such as DNA damage
Sabbatini et al., DNA Cell Biol 2002 : We demonstrate that MDMX dramatically inhibits the acetylation of p53 induced by both endogenous and ectopically expressed p300/CBP
Deng et al., Cancer Res 2005 (Cell Transformation, Neoplastic) : We further showed that p300/CBP were essential for ras induced p53 activity, providing a potential mechanism underlying the important role of p300/CBP in senescence
Sang et al., J Cell Biochem 1997 : Our data suggest that p300/CBP and TBP but not the pocket proteins, pRb, p107, and pRb2/p130 are functional targets of E1A in transcriptional regulation and that p53 transactivation requires the function of the p300/TBP/TFIIB complex, thus delineating a new pathway by which E1A may exert its transforming activity
Ravi et al., Cancer Res 1998 : p53 dependent transactivation and transrepression require its interaction with p300/CBP , a coactivator that also interacts with the RelA subunit of nuclear factor-kappaB
Lambert et al., J Biol Chem 1998 : CREB binding protein (CBP)/p300 , through its interaction with the N terminus of p53, acts as a coactivator for p53 and increases the sequence-specific DNA binding activity of p53 by acetylating its C terminus